Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07761845

Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for Mortality of Patients With Burn Injuries

The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain shams university

Cairo, Cairo Governorate, 11111, Egypt

Location status: Recruiting

About this study

The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.

Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.

After consent, Patients' characteristics (age, sex, weight), clinical parameters (Total burn surface area, Abbreviated burn severity index), and comorbidities will be recorded.

  • Emergency Department (ED) management (Arrival and Initial Stabilization)
  • Primary survey (ATLS principles): Immediate stabilization of Airway, Breathing, Circulation, Disability, Exposure (ABCDE).
  • Urinary catheter insertion to monitor urine output for proper resuscitation.
  • TBSA will be estimated using the Rule of Nines
  • All patients will be treated during the first 24 hours after burn injury guided by the Parkland Formula.
  • In-Hospital Resuscitation (0-72 h)
  • Hemodynamic monitoring: ECG, pulse oximetry, respiratory rate, temperature, non-invasive blood pressure, arterial line if unstable, and central venous pressure.
  • Transition to Day 2 (24-48 h post-burn):Continue Lactated Ringer's, and consider colloid therapy (5% albumin or plasma) after 24 h to maintain oncotic pressure and reduce crystalloid load.
  • Fluid adjustments according to urine output, mean arterial pressure with target MAP (≥65 mmHg), lactate clearance, and base deficit.

Laboratory and calculation:

On admission to ED, an arterial blood gas (ABG) sample will be collected to calculate base deficit (BD) and lactate level.

Simultaneously, venous blood will be drawn for C-reactive protein (CRP) and serum albumin, CBC, serum urea, creatinine, AST, ALT, and electrolyte's (NA+, K+, MG+) estimation.

Red Cell Distribution Width/Albumin will be calculated: as ((RDW (Standard Deviation of Red Blood Cell Volume / Mean Corpuscular Volume) × 100%.) / albumin (g/L) ))from admission labs .

Serial: Lactate/Base Defecit at 6hr, 12hr, 24hr as a monitor for proper resuscitation Calculation of Severity Scores

  • R-Baux score: Age (years) + %TBSA + (17 × inhalation injury [yes=1, no=0])
  • Abbreviated Burn Severity Index (ABSI): The ABSI includes five parameters: sex, age category, %TBSA , presence of full-thickness burns, and inhalation injury. Each parameter is assigned weighted points, and the total ABSI score is associated with graded survival probabilities (christ et al., 2024).

Both scores will be calculated on admission and compared with admission (RDW/albumin)ratio to assess relative and incremental predictive value for 30-day mortality.

Supportive care:

  • Early enteral nutrition, Proper multimodal analgesia (paracetamol 1gm/8hr, nalbuphine 0.1mg/kg if VAS score>4) , IV proton pump inhibitor to guard against curling ulcer, Prophylactic anticoagulation to guard against DVT.
  • Vasopressors(norepinephrine) only after adequate fluid resuscitation guided by UOP, lactate and BD if MAP below 65 mmHg.

3 - Post-Resuscitation and Definitive Management Protocol (After 72 h) Hemodynamic stabilization (post-resuscitation phase) Transition from resuscitation fluids to maintenance fluids. Avoid "fluid creep" (excess positive balance leading to pulmonary edema, abdominal compartment). → cautious use of diuretics to mobilize edema.

Maintain: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/h. Ongoing ventilatory support if required; lung-protective strategy for ARDS. Weaning as early as possible.

Infection prevention and sepsis monitoring

  • Daily wound assessment for signs of infection, weekly or targeted wound/blood cultures and antibiotics only if infection is suspected/proven (not prophylactic).

Wound care and surgical management

  • Regular dressing , Use of negative-pressure wound therapy when indicated.
  • Early excision and grafting after 72 hr, Pain and sedation control
  • Multimodal analgesia, pre-procedure analgesia for dressing/grafting and Long-term psychological and pain management .

Rehabilitation and functional recovery • Early physiotherapy, occupational therapy for daily living skills and Psychosocial support for patient and family.

Criteria for transfer to ward • Hemodynamically stable, off vasopressors.

  • Stable oxygenation without advanced ventilatory support.
  • Tolerating enteral feeding.
  • Wounds coverage completed or adequately covered with new TBSA% below 20%.
  • Patients will be followed for 30 days at Ain Shams University burn unit. Measured outcomes

Primary outcome:

To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30 days hospital mortality in burn patients.

Secondary outcomes:

To determine the correlation between Red Cell Distribution Width/Albumin with :

  • ICU length of stay
  • Hospital length of stay
  • Requirements of inotropes or vasopressors
  • Duration of mechanical ventilation
  • To compare RDW/albumin ratio with R-Baux score as a predictor of mortality in burn patient.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years.
  • Both sexes.
  • Patients with burn injuries (%TBSA >20%).
  • Availability of complete laboratory data (RDW, albumin)on admission .
  • Admission to ICU within 24 hours of burn injury.

Exclusion criteria

  • • Age <18 years old.
  • Patients with chronic hematologic disease.
  • Pre-existing liver disease.
  • Nephrotic syndrome, chemotherapy.
  • Patients with incomplete or missing lab records.
  • Pregnant females.
  • Patient or guardian refusal.

Treatment and study plan

Primary outcomes

  1. mortality in burn patients

    Time frame: 30 days

    To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30 days hospital mortality in burn patients.

Secondary outcomes

  1. ICU length of stay

    Time frame: 30 days

    To determine the correlation between Red Cell Distribution Width/Albumin with o ICU length of stay

  2. R-Baux score as a predictor of mortality in burn patient.

    Time frame: 30 days

    To compare RDW/albumin ratio with R-Baux score as a predictor of mortality in burn patient.

  3. Requirements of inotropes or vasopressors

    Time frame: 30 days

    To determine the correlation between Red Cell Distribution Width/Albumin with

    o Requirements of inotropes or vasopressors

  4. Duration of mechanical ventilation

    Time frame: 30 days

    To determine the correlation between Red Cell Distribution Width/Albumin with

    o Duration of mechanical ventilation

Study contacts

Contact information is provided by the study sponsor or research team.

Ahlam M abdelnaby. study principal investigator, MBBCH, MSc .

CONTACT

[email protected]

+201120327604

Sara H Saleh, MD

CONTACT

+201001584305

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Measurement of Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for 30-day Mortality of Patients With Burn Injuries

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 12, 2026
Registry last updated
Aug 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.